• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of clinically applicable cell transplantation therapies

Research Project

Project/Area Number 18K15715
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 52050:Embryonic medicine and pediatrics-related
Research InstitutionShimane University

Principal Investigator

Oda Yasuaki  島根大学, 医学部, 助教 (70602473)

Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Keywords低ホスファターゼ症 / 再生医療 / 間葉系幹細胞 / 細胞移植 / iPS細胞 / 難病
Outline of Final Research Achievements

Hypophosphatasia is a rare bone disease that presents with severe osteogenesis imperfecta due to mutations in the ALPL gene. In this study, using with hypophosphatasia model mice (Alpl -/- mice), we developed a basic technology for cell transplantation therapy using ultra-high-purity mesenchymal stem cells (MSC), which have extremely high differentiation, proliferation, and migration ability.
Mouse bone marrow cells and human ultra-high purity MSCs were transplanted into X-ray irradiated Alpl -/- mice. Two month later, I prepared frozen slices of mouse femur to examine alkaline phosphatase (ALP) activity, which is an indicator of bone-producing osteoblasts. ALP activity derived from human ultra-high purity MSC was detected only in the transplanted group. And the survival rate has also improved significantly.

Academic Significance and Societal Importance of the Research Achievements

現在、低ホスファターゼ症の治療薬は酵素製剤(製品名:ストレンジック)のみであるが、生涯にわたって投薬が必要であり、投薬を続けることで中和抗体(薬の効果を打ち消してしまう抗体ができること)が出現する懸念がある。
本研究成果は、ヒト超高純度MSC移植という、低ホスファターゼ症に対する新たな治療法の選択肢を提案すると共に、併用することでより相乗的な効果が期待される。ヒト高純度MSC移植のみで治療が可能になれば、根治療法となり得る可能性も秘めている。低ホスファターゼ症のみならず、他の骨系統疾患にも適応できると考えられるため、学術的にも社会的にも大きな意義があると考える。

Report

(2 results)
  • 2020 Final Research Report ( PDF )
  • 2018 Research-status Report
  • Research Products

    (1 results)

All 2019

All Book (1 results)

  • [Book] Human Pathobiochemistry2019

    • Author(s)
      Taketani T., Oyama C., Oda Y., Murphy L.
    • Total Pages
      349
    • Publisher
      Springer
    • ISBN
      9789811329777
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi